Overview

This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.

Eligibility

Inclusion Criteria:

• Age ≥18-≤75 years.
• Histologically confirmed diagnosis.
• One of the forms of the cervical cancer:
  1. Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
  2. Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
  3. Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).
• Availability of material for determining PD-L-1 expression for immunotherapy candidates.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• No contraindications to chemotherapy, immunotherapy, or bevacizumab.
• Signed informed consent to participate in the study.

Exclusion Criteria:

• Presence of another active malignant invasive neoplasm.
• Pregnancy or lactation period.